JP2024538787A - ヒトｔｒｐｖ６チャネルの細胞外エピトープに対する抗体並びにこれらの診断的及び治療的使用 - Google Patents

ヒトｔｒｐｖ６チャネルの細胞外エピトープに対する抗体並びにこれらの診断的及び治療的使用 Download PDF

Info

Publication number
JP2024538787A
JP2024538787A JP2024522356A JP2024522356A JP2024538787A JP 2024538787 A JP2024538787 A JP 2024538787A JP 2024522356 A JP2024522356 A JP 2024522356A JP 2024522356 A JP2024522356 A JP 2024522356A JP 2024538787 A JP2024538787 A JP 2024538787A
Authority
JP
Japan
Prior art keywords
seq
antibody
trpv6
chain variable
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538787A5 (enExample
Inventor
ナターリャ・プレヴァルスカヤ
ヴャチェスラフ・レーヘンキー
オーレリアン・オストラート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Publication of JP2024538787A publication Critical patent/JP2024538787A/ja
Publication of JP2024538787A5 publication Critical patent/JP2024538787A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
JP2024522356A 2021-10-14 2022-10-14 ヒトｔｒｐｖ６チャネルの細胞外エピトープに対する抗体並びにこれらの診断的及び治療的使用 Pending JP2024538787A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306438.9 2021-10-14
EP21306438 2021-10-14
PCT/EP2022/078728 WO2023062226A2 (en) 2021-10-14 2022-10-14 Antibodies against extracellular epitopes of human trpv6 channel and their diagnostic and therapeutic uses

Publications (2)

Publication Number Publication Date
JP2024538787A true JP2024538787A (ja) 2024-10-23
JP2024538787A5 JP2024538787A5 (enExample) 2025-07-04

Family

ID=78820597

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522356A Pending JP2024538787A (ja) 2021-10-14 2022-10-14 ヒトｔｒｐｖ６チャネルの細胞外エピトープに対する抗体並びにこれらの診断的及び治療的使用

Country Status (9)

Country Link
US (1) US20250236666A1 (enExample)
EP (1) EP4416181A2 (enExample)
JP (1) JP2024538787A (enExample)
KR (1) KR20240099277A (enExample)
CN (1) CN118401554A (enExample)
AU (1) AU2022365387A1 (enExample)
CA (1) CA3235233A1 (enExample)
WO (1) WO2023062226A2 (enExample)
ZA (1) ZA202403415B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260116965A1 (en) * 2021-01-15 2026-04-30 Coherent Biopharma (Suzhou) , Limited Anti-trpv6 monoclonal antibody and application thereof
CN120590523B (zh) * 2025-06-20 2026-01-27 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种犬瘟热病毒n蛋白单克隆抗体，快速检测胶体金试纸条及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005119262A2 (en) * 2004-05-27 2005-12-15 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production
JP5749154B2 (ja) 2008-03-19 2015-07-15 ソリシメド・バイオファーマ・インコーポレーテッド Ｔｒｐｖ６カルシウムチャネル活性阻害による癌治療のためのペプチド組成物
EP2445932B1 (en) * 2009-06-26 2018-02-28 Soricimed Biopharma Inc. Soricidin derived peptides and methods for the detection of trpv-6 cancers and drug delivery
US20260116965A1 (en) * 2021-01-15 2026-04-30 Coherent Biopharma (Suzhou) , Limited Anti-trpv6 monoclonal antibody and application thereof

Also Published As

Publication number Publication date
EP4416181A2 (en) 2024-08-21
US20250236666A1 (en) 2025-07-24
CA3235233A1 (en) 2023-04-20
WO2023062226A2 (en) 2023-04-20
ZA202403415B (en) 2025-08-27
AU2022365387A1 (en) 2024-05-02
WO2023062226A3 (en) 2023-05-25
KR20240099277A (ko) 2024-06-28
CN118401554A (zh) 2024-07-26

Similar Documents

Publication Publication Date Title
US20250019461A1 (en) Her3 antigen-binding molecules
KR102699503B1 (ko) 암 진단에 유용한 클라우딘 18.2에 대한 항체
KR20220086554A (ko) Her3 항원-결합 분자를 사용한 암의 치료 및 예방
US20140193417A1 (en) Membrane Transporter NaPi2b (SCL34A2) Epitope for Antibody Therapy, Antibodies Directed Thereto, and Target for Cancer Therapy
US20030096285A1 (en) Identifying anti-tumor targets or agents by lipid raft immunization and proteomics
BR112020025502A2 (pt) Anticorpos il-11ra
RS64937B1 (sr) Postupci i kompozicije za dijagnozu i lečenje kancera
BR112012032008B1 (pt) Anticorpos s100a4, linhagem celular de hibridoma, composição farmacêutica, conjugado, método e kit para diagnosticar câncer ou uma doença associada à inflamação
US10501549B2 (en) Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
EP3768701A1 (en) Wnt signaling agonist molecules
KR20210134705A (ko) 절단형의 변이형 Calreticulin에 결합하는 항체, 및 골수 증식성 종양의 진단, 예방 또는 치료약
JP2024538787A (ja) ヒトｔｒｐｖ６チャネルの細胞外エピトープに対する抗体並びにこれらの診断的及び治療的使用
JP2022500072A (ja) Ｎｔｓｒ１に特異的な抗体およびその使用
TWI790992B (zh) 抗ｔｍｅｍ-１８０抗體、抗癌劑、及癌之檢查方法
US20250122303A1 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
CN113710273A (zh) 通过靶向驻留在癌细胞上的角蛋白14(krt14)的细胞外部分治疗或预防癌症的方法
CN104470950B (zh) 抗cxadr抗体
CN103201291B (zh) 抗单链iv型胶原多肽抗体和包含其的用于诊断、预防或治疗肿瘤的药物或药剂
US10202459B2 (en) Methods of inhibiting pathological angiogenesis with doppel-targeting molecules
JP2023530997A (ja) Ｂｓｔ２ロングアイソフォームを標的化する抗ｂｓｔ２抗体
EP3145545B1 (en) Bak binding proteins
US20240034776A1 (en) Use of regulator of itpripl1 in preparation of drug that regulates immune responses or fights tumors
WO2018164441A1 (en) Methods of inhibiting pathological angiogenesis with doppel-targeting molecules

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260421